Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Saher Nasir Amin"'
Publikováno v:
Transplantation and Cellular Therapy. 28:S344-S345
Publikováno v:
Journal of Clinical Oncology. 40:e16231-e16231
e16231 Background: Pancreatic cancer is the 11th most common cancer and represents 3.2% of all new cancer cases. But it is the third leading cause of cancer-related deaths with a five-year relative survival of only 10.8%. More than 50% of patients di
Autor:
Saad Ullah Malik, Saher Nasir Amin, David Sharon, Muhammad Sardar, Raza Naseer, Qistas Ahmad, Patrick Lee, Muhammad Abuzar, Chaudhry Saad Sohail, Ali McBride, Ahmed Safdar, Muhammad Idrees, Rajshekhar Chakraborty, Faiz Anwer, Ali Younas Khan
Publikováno v:
Journal of Hematology
Ibrutinib has shown to have better efficacy than standard chemoimmunotherapy in del17 positive chronic lymphocytic leukemia (CLL) patients; however its role in del17 negative patients is less clear. We aim to evaluate the efficacy of ibrutinib-based
Autor:
Saher Nasir Amin, Faiz Anwer, Karun Neupane, Adeel Masood, Ahsan Wahab, Hamid Ehsan, Moazzam Shahzad, Tehniat Faraz Ahmed, Pranali Santhoshini Pachika, Muhammad Umair Mushtaq, Razwana Khanam
Publikováno v:
Journal of Clinical Oncology. 39:e20042-e20042
e20042 Background: Light-chain deposition disease (LCDD) is part of a wide spectrum of plasma cell proliferation disorders. LCDD predominantly affects kidneys by systemic deposition of congo red negative non-fibrillar light chains. Due to the rarity
Autor:
Malik Qistas Ahmad, Ceren Durer, Ahmad Safdar, Muhammad Junaid Tariq, Muhammad Yasir, Awais Ijaz, Saher Nasir Amin, Muhammad Usman, Seren Durer, Sharoon Samuel, Nadia Carenina Nunes Cavalcante Parr, Faiz Anwer, Muhammad Jahanzeb Khalil, Muhammad Asad Fraz
Publikováno v:
Blood. 132:5656-5656
Introduction Immunotherapy using monoclonal antibodies (mAbs) have been gaining significance in the treatment of multiple myeloma (MM). These include naked antibodies, checkpoint inhibitors (CPIs), novel bispecific mAbs targeting two epitopes and ant
Autor:
Muhammad Yasir, Awais Ijaz, Shehroz Aslam, Muhammad Junaid Tariq, Arafat Ali Farooqui, Seren Durer, Faiz Anwer, Malik Qistas Ahmad, Ceren Durer, Sharoon Samuel, Muhammad Jahanzeb Khalil, Muhammad Asad Fraz, Amna Khalid, Muhammad Usman, Saher Nasir Amin
Publikováno v:
Blood. 132:5231-5231
Introduction Selinexor, a SINE (selective inhibitor of nuclear export) compound, inhibits exportin 1 (XPO1) involved in transport of tumor suppressor proteins leading to apoptosis of tumor cells. XPO1 is overexpressed in variety of cancer including o
Autor:
Faiz Anwer, Muhammad Azharuddin, Rajshekar Chakraborty, David Sharon, Ali Younas Khan, Chaudhry Saad Sohail, Patrick Lee, Ali McBride, Saad Ullah Malik, Warda Faridi, Malik Qistas Ahmad, Saher Nasir Amin, Muhammad Sardar
Publikováno v:
Blood. 132:5563-5563
Background: Treatment of Chronic lymphocytic leukemia (CLL) depends on stage of disease, age, functional status, comorbidities and presence of cytogenetic abnormalities such as (del17p mutation). Ibrutinib was initially approved in CLL given its bett
Autor:
Ceren Durer, Muhammad Yasir, Isin Y Comba, Insija Ilyas Selene, Anum Qureshi, Muhammad Asad Fraz, Shehroz Aslam, Jemin Aby Jose, Seren Durer, Emmanuel Katsanis, Mustafa Nadeem Malik, Saher Nasir Amin, Zunairah Shah, Faiza Jamil, Faiz Anwer
Publikováno v:
Blood. 132:5779-5779
Background: Ex-vivo T-cell-depleted graft is used to prevent acute and chronic GVHD for haploidentical hematopoietic SCT (HSCT). We conducted a systematic review and meta-analysis to evaluate the outcomes of T-cell-depleted grafts for peripheral bloo